E5555

DRUG4 trials

Sponsors

Eisai Inc., Eisai Co., Ltd.

Conditions

Acute Coronary SyndromeCoronary Artery DiseaseHealthy Subjects

Phase 1

Randomized, Placebo-controlled Study to Evaluate Effects of E5555 on Renal Function Parameters and OCT2 Activity

CompletedNCT01241669

Eisai Inc.Healthy Subjects

Start: 2010-10-31Updated: 2014-07-11

Phase 2

Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease

CompletedNCT00312052

Eisai Inc.Coronary Artery Disease

Start: 2007-09-30End: 2009-08-31Updated: 2016-12-05

Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Acute Coronary Syndrome

CompletedNCT00548587

Eisai Inc.Acute Coronary Syndrome

Start: 2007-10-31End: 2009-08-31Updated: 2016-02-04

A Double-Blind Study of E5555 in Japanese Patients With Acute Coronary Syndrome

CompletedNCT00619164

Eisai Co., Ltd.Acute Coronary Syndrome

Start: 2007-11-30Updated: 2013-05-13

Related Papers

Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial.

2011-04-18108 citations

Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial.

2011-04-1892 citations